Residual Disease
Showing 1 - 25 of >10,000
Minimal Residual Disease Using Multi-omics Approach
Not yet recruiting
- Pancreatic Ductal Adenocarcinoma
- Blood collection and Pancreatic ductal adenocarcinoma minimal residual disease detection test
-
Shanghai, ChinaDepartment of Pancreatic and Hepatobiliary Surgery, Fudan Univer
Nov 29, 2023
Minimally Residual of Esophageal Cancer 001
Recruiting
- Esophageal Carcinoma
- Minimal Residual Disease
-
Shijiazhuang, Hebei, ChinaFourth Hospital of Hebei Medical University
Jul 17, 2023
AML, Adult, Minimal Residual Disease Trial (MRD assessment)
Not yet recruiting
- AML, Adult
- Minimal Residual Disease
- MRD assessment
- (no location specified)
Oct 13, 2023
Renal Cell Carcinoma Trial in Birmingham (Pembrolizumab injection)
Not yet recruiting
- Renal Cell Carcinoma
- Pembrolizumab injection
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Aug 20, 2023
GUIDING MULTI-MODAL THERAPIES AGAINST MINIMAL RESIDUAL DISEASE
Enrolling by invitation
- Pancreatic Adenocarcinoma
- liquid biopsy
-
Stockholm, SwedenGastrocentrum, KarolinskaUniversity Hospital
Oct 26, 2023
MRD-tailored Therapy in Newly Diagnosed Multiple Myeloma With
Not yet recruiting
- Multiple Myeloma
- Minimal Residual Disease
- (no location specified)
Nov 1, 2023
B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia Trial in Tampa (Tecartus)
Recruiting
- B-Cell Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia
-
Tampa, FloridaMoffitt Cancer Center
Nov 28, 2023
Digital Droplet PCR in Early Period After Allo-HSCT to Predict
Completed
- Measurable Residual Disease
- Digital Droplet PCR
-
Hangzhou, Zhejiang, ChinaThe First Hospital of Zhejiang Medical Colleage Zhejiang Univers
Aug 17, 2023
Next-generation Sequencing in Pediatric B-ALL Children Patients
Not yet recruiting
- Acute Lymphoblastic Leukemia, Pediatric
- (no location specified)
Apr 19, 2023
Minimal Residual Disease Trial in Tianjin (QN-030a, Cyclophosphamid, Fludarabine)
Recruiting
- Minimal Residual Disease
- QN-030a
- +3 more
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Nov 3, 2022
Stage II-III Gastric Cancer Trial in Jinan, Qingdao, Yantai (MRD-guided therapy)
Recruiting
- Stage II-III Gastric Cancer
- MRD-guided therapy
-
Jinan, Shandong, China
- +4 more
Nov 27, 2023
Pancreatic Cancer, Advanced Cancer, Metastatic Cancer Trial in Beijing (Later-line therapy)
Recruiting
- Pancreatic Cancer
- +2 more
- Later-line therapy
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Apr 10, 2023
Measurable Residual Disease in Acute Myeloid Leukemia as
Terminated
- Leukemia, Myeloid, Acute
- Measurable residual disease measured by flow cytometry
-
Heidelberg, BW, GermanyUniversity Hospital Heidelberg
Sep 12, 2022
Ovarian Cancer Trial in Houston (Pembrolizumab, Bevacizumab, Cyclophosphamide)
Not yet recruiting
- Ovarian Cancer
- Pembrolizumab
- +2 more
-
Houston, TexasMD Anderson Cancer Center
Oct 9, 2023
Pancreatic Cancer, Resectable Carcinoma Trial in Beijing (Later-line therapy)
Recruiting
- Pancreatic Cancer
- Resectable Carcinoma
- Later-line therapy
-
Beijing, ChinaDepartment of Medical Oncology, Peking Union Medical College Hos
Apr 10, 2023
Rectal Cancer Patients Based on ctDNA-MRD Technology
Recruiting
- Rectal Adenocarcinoma
- +3 more
- MRD detection
-
Guangzhou, Guangdong, ChinaWeiWei Xiao
Jul 31, 2023
Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Trial (Monalizumab, Cetuximab)
Not yet recruiting
- Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
- Monalizumab
- Cetuximab
- (no location specified)
Jan 8, 2023
Acute Myeloid Leukemia, Leukemia, Leukemia, Myeloid Trial in Boston (Cytokine Induced Memory-like Natural Killer Cells,
Not yet recruiting
- Acute Myeloid Leukemia
- +5 more
- Cytokine Induced Memory-like Natural Killer Cells
- Interleukin-2
-
Boston, Massachusetts
- +1 more
Nov 14, 2023
Pancreatic Cancer, Locally Advanced Trial in Beijing (Later-line therapy)
Recruiting
- Pancreatic Cancer
- Locally Advanced
- Later-line therapy
-
Beijing, ChinaDepartment of Medical Oncology, Peking Union Medical College Hos
Apr 10, 2023
Danish Assessment of Minimal Residual Disease by Liquid Biopsies
Recruiting
- Colorectal Neoplasms
- +5 more
-
Copenhagen, Capital Region Of Denmark, Denmark
- +8 more
Oct 13, 2023
Novel Digital Array PCR for Acute Myeloid Leukemia (AML)
Recruiting
- Leukemia, Myeloid, Acute
- Minimal Residual Disease
-
Chapel Hill, North CarolinaNorth Carolina Cancer Hospital (NCCH)
Feb 2, 2023
MDS Trial in Saint Louis (DEC-C, MyeloSeq-HD)
Recruiting
- Myelodysplastic Syndromes
- DEC-C
- MyeloSeq-HD
-
Saint Louis, MissouriWashington University School of Medicine
Jan 18, 2023
Leukemia, Lymphoma Trial in Houston (Ofatumumab)
Active, not recruiting
- Leukemia
- Lymphoma
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Dec 9, 2022
Lymphoma Trial in Houston (cell-free DNA)
Not yet recruiting
- Lymphoma
- cell-free DNA
-
Houston, TexasMD Anderson Cancer Center
Dec 22, 2022